The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
The iron chelator deferasirox enhances liposomal amphotericin B efficacy in treating murine invasive pulmonary aspergillosis
Open accessAbstract
OBJECTIVES: Increased bone marrow iron levels in patients with haematological malignancies is an independent risk factor for developing invasive pulmonary aspergillosis (IPA), suggesting an important role for iron uptake in the pathogenesis of IPA. We sought to determine the potential for combination therapy with the iron chelator deferasirox + liposomal amphotericin B (LAmB) to improve the outcome of murine IPA compared with LAmB monotherapy. METHODS: In vitro MIC and minimum fungicidal concentration (MFC) values of the iron chelator, deferasirox, for Aspergillus fumigatus were determined by microdilution assay. In addition, we studied the efficacy of deferasirox alone or combined with LAmB in treating immunocompromised mice infected with A. fumigatus via inhalation. RESULTS: Deferasirox was cidal in vitro against A. fumigatus, with an MIC and MFC of 25 and 50 mg/L, respectively. Deferasirox monotherapy modestly prolonged survival of mice with IPA. Combination deferasirox + LAmB therapy synergistically improved survival and reduced lung fungal burden compared with either monotherapy alone. CONCLUSIONS: Iron chelation therapy with deferasirox alone or in combination with LAmB is effective in treating experimental IPA. Further study of deferasirox is warranted as adjunctive therapy for IPA infections.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“High iron modulates the gut microbiome [22]”
From High iron-mediated increased oral fungal burden, oral-to-gut transmission, and changes to pathogenicity of Candida albicans in oropharyngeal candidiasis (2022) · cites this paper as [22]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis
Herbrecht, R., Denning, D. W., Patterson, T. F., Bennett, J. E., Greene, R. E., Oestmann, J.-W., Kern, W. V., Marr, K. A., Ribaud, P., Lortholary, O., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020191 · Cited by 3,304
Invasive Aspergillosis in 2002: An Update
Kontoyiannis, D., & Bodey, G. (2002) · European Journal of Clinical Microbiology and Infectious Diseases · doi:10.1007/s10096-002-0699-z · Cited by 326
The iron chelator deferasirox protects mice from mucormycosis through iron starvation
Ibrahim, A. S., Gebermariam, T., Fu, Y., Lin, Husseiny, M. I., French, S. W., Schwartz, J., Skory, C. D., Edwards, J. E., & Spellberg, B. J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32338 · Cited by 308
Self-citationHissen, A. H. T., Wan, A. N. C., Warwas, M. L., Pinto, L. J., & Moore, M. M. (2005) · Infection and Immunity · doi:10.1128/iai.73.9.5493-5503.2005 · Cited by 243
Deferiprone iron chelation as a novel therapy for experimental mucormycosis
Ibrahim, A. S., Edwards, J. E., Fu, Y., & Spellberg, B. J. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl350 · Cited by 156
Self-citationKontoyiannis, D. P., Chamilos, G., Lewis, R. E., Giralt, S., Cortes, J., Raad, I. I., Manning, J. T., & Han, X. (2007) · Cancer · doi:10.1002/cncr.22909 · Cited by 152
Novel Inhalational Murine Model of Invasive Pulmonary Aspergillosis
Sheppard, D. C., Rieg, G. K., Chiang, L. Y., Filler, S. G., Edwards, J. E., & Ibrahim, A. S. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.5.1908-1911.2004 · Cited by 139
Self-citationAltés, A., Remacha, A. F., Sardà, P., Sancho, F. J., Sureda, A. M., Martino, R., Briones, J., Brunet, S., Canals, C., & Sierra, J. (2004) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1704628 · Cited by 128
Zarember, K. A., Cruz, A. R., Huang, C.-Y., & Gallin, J. I. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01547-08 · Cited by 78
Cited by
ESCMID† and ECMM‡ joint clinical guidelines for the diagnosis and management of mucormycosis 2013
Cornely, O. A., Arikan-Akdagli, S., Dannaoui, E., Groll, A. H., Lagrou, K., Chakrabarti, A., Lanternier, F., Pagano, L., Skiada, A., Akova, M., et al. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12371 · Cited by 863
Iron in infection and immunity
Nairz, M., & Weiss, G. (2020) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2020.100864 · Cited by 359
HapX-Mediated Adaption to Iron Starvation Is Crucial for Virulence of Aspergillus fumigatus
Schrettl, M., Beckmann, N., Varga, J., Heinekamp, T., Jacobsen, I. D., Jöchl, C., Moussa, T. A., Wang, S., Gsaller, F., Blatzer, M., et al. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1001124 · Cited by 284
Iron - a key nexus in the virulence of Aspergillus fumigatus
Haas, H. (2012) · Frontiers in Microbiology · doi:10.3389/fmicb.2012.00028 · Cited by 217
Hsu, P.-C., Yang, C.-Y., & Lan, C.-Y. (2011) · Eukaryotic Cell · doi:10.1128/ec.00158-10 · Cited by 157
Metadata
- Authors
- Ibrahim, A. S., Gebremariam, T., French, S. W., Edwards, J. E., & Spellberg, B.
- Affiliations
- University of California, Los Angeles (US)
- Corresponding author
- Ibrahim, A. S.
- Venue
- Journal of Antimicrobial Chemotherapy
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-11-26
- Volume
- 65
- Issue
- 2
- Pages
- 289-292
- ISSN
- 0305-7453 (ISSN-L)
- 1460-2091
- PMC
- PMC2902852
- OpenAlex
- W2160870988
- Cited by
- 68
- References
- 9
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 1 · 2023: 3 · 2022: 5 · 2021: 2 · 2020: 3 · 2019: 2 · 2018: 4 · 2017: 3 · 2016: 6 · 2015: 3 · 2014: 6 · 2013: 11 · 2012: 3
- FWCI
- 2.99
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Antimicrobial Chemotherapy (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Funders
- Gilead Sciences
- National Institute of Allergy and Infectious Diseases (R21AI064716, R01AI063503)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
- Keywords
- deferasirox, liposomal amphotericin B, invasive pulmonary aspergillosis, Aspergillus fumigatus, iron chelation, combination antifungal therapy, antifungal synergy, immunocompromised patients, hematologic malignancies, bone marrow iron, antifungal susceptibility
- MeSH terms
- Deferasirox, Amphotericin B, Animals, Antifungal Agents, Aspergillus fumigatus, Benzoates, Drug Synergism, Drug Therapy, Combination, Humans, Male, Mice, Inbred BALB C, Microbial Sensitivity Tests, Triazoles, Survival Analysis, Treatment Outcome, Microbial Viability, Mice, Invasive Pulmonary Aspergillosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The iron chelator deferasirox enhances liposomal amphotericin B efficacy in treating murine invasive pulmonary aspergillosis. https://app.cochat.ai/papers/10.1093/jac/dkp426
- The paper
- Ibrahim, A. S., Gebremariam, T., French, S. W., Edwards, J. E., & Spellberg, B. (2010). The iron chelator deferasirox enhances liposomal amphotericin B efficacy in treating murine invasive pulmonary aspergillosis. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkp426
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.